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Abstract
The ability to obtain gene expression profiles from human disease specimens provides an 
opportunity to identify relevant gene pathways, but is limited by the absence of data sets spanning 
a broad range of conditions. Here, we analyzed publicly available microarray data from 16 diverse 
skin conditions in order to gain insight into disease pathogenesis. Unsupervised hierarchical 
clustering separated samples by disease and common cellular and molecular pathways. Disease 
specific signatures were leveraged to build a multi-disease classifier which predicted the diagnosis 
of publicly and prospectively collected expression profiles with 93% accuracy. In one sample, the 
molecular classifier differed from the initial clinical diagnosis and correctly predicted the eventual 
diagnosis as the clinical presentation evolved. Finally, integration of interferon (IFN) regulated 
gene programs with the skin database revealed a significant inverse correlation between IFN–β 
and IFN–γ programs across all conditions. Our study provides an integrative approach to the study 
of gene signatures from multiple skin conditions, elucidating mechanisms of disease pathogenesis. 
Additionally, these studies provide a framework for developing tools for personalized medicine 
towards the precise prediction, prevention, and treatment of disease on an individual level.
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Introduction
Gene expression profiling technology, such as microarrays, provides the opportunity to 
identify disease specific genes and pathways. The NCBI Gene Expression Omnibus (GEO) 
is a community resource of publicly available experimental data sets including those 
involving human health and disease and that incorporate less common diseases studied in 
specific laboratories (Edgar et al., 2002). This searchable database contains annotated gene 
expression profile data (both in summarized and raw formats), primarily from published 
work. The ability to mine data from GEO provides a tremendous opportunity to compare 
gene expression profiles across multiple diseases.
Previously, disease profiles have been compared across multiple data sets by normalizing to 
controls within each set; however, this practice limits the use of available data to those 
containing equivalent control profiles (Chaussabel et al., 2008; Wong et al., 2012). To 
overcome this limitation, data integration from multiple sources, particularly those from 
experiments containing a single disease, can be achieved with Frozen Robust Multi-array 
Average (fRMA), which normalizes samples to a standard reference set of microarrays, 
eliminating the need for control samples in each data set (McCall et al., 2010). Here we 
present a study that uses this approach on gene expression profiles derived from skin biopsy 
specimens. We assembled a database of publicly available skin microarray samples 
representing 16 inflammatory, infectious, and neoplastic conditions. This database was used 
to construct a classifier, perform functional analyses to identify representative pathways, and 
establish a spectrum of differentially expressed Type I vs. Type II interferon gene programs 
across these diseases (Figure S1).
Results
Data normalization with Frozen RMA
We searched GEO for microarray experiments performed on human skin samples associated 
with a dermatological disorder (www.ncbi.nlm.nih.gov/geo) (Edgar et al., 2002). Data for 
microarrays 311 skin biopsy samples were downloaded, representing 16 conditions from 15 
experiments and 14 laboratories (Table S1). All samples used the Affymetrix HG U133 Plus 
2.0 platform. To analyze this data as a single set, Frozen RMA (fRMA) was used to 
normalize samples such that they showed comparable probe set intensity distributions 
(Figure S2) (McCall et al., 2010).
After unsupervised gene clustering, samples segregate by disease and into groups with 
related pathogenesis
In order to determine whether the batch effects within a given disease were smaller than the 
differences between diseases, trees of filtered gene expression profiles were constructed for 
both samples and diseases (Figures 1, S3). Remarkably, we found that in diseases in which 
there were multiple batches of microarrays from different sources, including psoriasis, 
atopic dermatitis and leprosy, batches from the same disease nearly always clustered 
together, despite coming from independent data sets (Figure 1). Furthermore, five batches of 
normal skin, each obtained from healthy control subjects from different laboratories, 
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clustered together with little differentiation by batch. However, batch effects were not 
completely eliminated as samples from specific diseases often separated by lab or 
experiment. There were isolated cases of individual samples clustering with the incorrect 
disease. However, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) samples 
from a single lab were split into two groups. Overall, these results suggest that the use of 
fRMA allows us to minimize the effect of batch and allow true disease signatures to 
predominate.
When the higher-level structure of the tree was examined, we found that branches of the tree 
could be annotated as disease groups with related pathogenesis. These distinct groups were 
categorized according to the following descriptions: i) keratinocyte proliferation and 
neoplastic growth (psoriasis, and approximately half the SCC and BCC samples), ii) wound 
(post-operative wound, burn), iii) normal, iv) allergic (allergic contact dermatitis, atopic 
dermatitis), v) malignant (mycosis fungoides, melanoma); and, vi) infectious (leprosy, 
chancroid). These relationships are consistent with those seen in an unrooted disease tree, 
which was built with one leaf per disease by averaging distances between all pairs of 
samples (Figure S3).
Proportional median metric for identifying disease specific gene signatures
Gene signatures were identified for each disease in order to build a disease classifier and 
perform downstream functional analysis. We developed the “proportional median” (PM) 
metric to identify highly expressed gene probe sets for each disease. The PM of a microarray 
probe set X in disease Y represents how highly expressed X was in Y, compared to all other 
diseases. Probe sets were ranked by PM for each disease. Because lowly ranked genes often 
have low intensity and tend to be noisier than those with higher ranks, subsequent analysis 
utilized genes with high PM values, reflecting over-expression in a particular disease (Mutch 
et al., 2002; Tu et al., 2002). The top 25 genes in the psoriasis PM list were confirmed by 
comparison to RNA-seq data derived from the same samples (Figure S4) (Li et al., 2014).
Random forest classifier accurately predicts disease diagnosis
We built a random forest multi-classifier using our disease expression profiles to predict 
disease status based on the expression of a limited number of genes (Breiman, 2001). 
Briefly, the random forest algorithm selects subsets of samples and genes to iteratively build 
multiple, parallel decision trees. This random subsampling and iteration reduces the effect of 
noise and outliers on classifier training. In addition, cross-validation is built into the 
classifier training process by testing each decision tree with samples not used to build that 
tree.
We used PM to select the most informative probe sets as input to our classifier, which 
yielded an overall error rate of 4.5% (Figure S5). Performance for each disease was assessed 
by sensitivity, specificity, precision, and F1 score, a measure of accuracy equivalent to a 
weighted average of sensitivity and precision that has values between 0 (poor accuracy) and 
1 (perfect accuracy). Sensitivity values ranged from 0.60 and 1.00 (mean 0.92) and 
specificity values ranged from 0.99 to 1.00, which corresponds to an average of 92% of 
disease samples being accurately classified and 99% of negative classifications being 
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correct. The range of F1 scores was from 0.75 to 1.00 (mean 0.94) (Table S3). We also 
performed three-fold cross validation, which yielded aggregate F1 scores from 0.75 to 1.00 
(mean 0.96) (Table S4).
To assess the classifier’s ability to generalize, two-fold cross validation with separation by 
batch was carried out. We separated data into two approximately equal groups: in multi-
batch conditions (leprosy, psoriasis, atopic dermatitis, and normal), data was separated 
according to batch; otherwise, data was randomly partitioned. Two independent classifiers 
were built, each trained on one partitioned set and tested on the other. PM values used in 
feature selection were computed from only one group of data to ensure that test data did not 
bias classification. Diseases separated by batch had F1 scores between 0.90 and 0.95 (mean 
0.92), and diseases randomly separated had F1 scores between 0.71 and 1.00 (mean 0.92), 
indicating little loss of accuracy with batch separated cross validation (Table 1).
The classifier’s performance was next tested on data not used for any of the previous 
analyses, including the feature selection and training steps of this classifier. We generated 26 
de-identified gene expression profiles derived from biopsy specimens of leprosy, psoriasis, 
atopic dermatitis, and normal skin. We also found public data for 168 gene expression 
profiles derived from biopsy specimens of psoriasis, atopic dermatitis, and melanoma (Table 
S5). The classifier was used to assess these 194 validation samples, yielding an overall 
sensitivity of 0.93, specificity of 0.99, and F1 statistics between 0.76 and 1.0 (Table S6).
Upon follow-up of the patients from whom we had collected samples, we discovered that 
one that was clinically diagnosed with atopic dermatitis, which we classified as psoriasis, 
had an unusual presentation. This patient had a history of an atopic diathesis including hay 
fever, increased total IgE levels as well as elevated levels of the eosinophilic cationic 
protein. The patient presented clinically with chronic dermatitis on the palms of the hands, 
as well as on the plantar side of the feet. Furthermore, inflammatory skin lesions on the arms 
and other locations were clinically diagnosed as atopic dermatitis, consistent with the atopic 
diathesis, and a sample was obtained for the present study. However, later the patient 
developed inflammatory plaques on the lower back, which were clinically diagnosed as 
psoriasis. Both atopic dermatitis and psoriasis were considered as a diagnosis for this patient 
at various stages; however, the co-occurrence of atopic dermatitis and psoriasis is rare, 
perhaps due to the opposing immunopathogenic mechanisms for the two diseases (Beer et 
al., 1992; Eyerich et al., 2011; Henseler and Christophers, 1995). Although we cannot be 
certain of the initial diagnosis, our molecular classifier correctly predicted the diagnosis as 
the clinical course evolved.
Functional annotation of related disease signatures using cell-type specific deconvolution 
and k-means clustering shows shared and unique mechanisms of disease
We investigated whether diseases that grouped together on the hierarchical clustering tree 
shared cell types in their associated lesions. Using cell-type specific gene signatures 
developed in previous work by Swindell, et al., the relative enrichment of each cell type 
signature was assessed in each disease, and subjected to hierarchical clustering using 
Euclidian distance (Figure 2) (Swindell et al., 2013; Swindell et al., 2012).
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In some instances, the clustering by cell-type signatures was consistent with the hierarchical 
clustering and unrooted trees generated from the entire filtered gene profiles (Figures 1, S3). 
For example, atopic dermatitis, allergic contact dermatitis and normal skin clustered together 
in both trees, and deconvolution analysis revealed a T regulatory cell gene signature 
consistent with previous studies of atopic dermatitis expression profiles (Figure 2) (Clark 
and Kupper, 2007; Hanafusa et al., 2013). The notable absence of a general T cell specific 
signature in psoriasis and atopic dermatitis likely reflects that expression of T cell specific 
genes is much greater in conditions such as mycosis fungoides and Stevens Johnson 
syndrome, which are characterized by marked T cell activation and proliferation (Chung et 
al., 2008; Nassif et al., 2004; Yamashita et al., 2012). In other instances, the clustering 
differed by cell type versus hierarchical clustering, suggesting that other factors must be 
involved in the observed groupings.
We used pathway analysis of gene signatures to further investigate common pathways 
within each disease group. For each group of diseases indicated by hierarchical clustering, 
combined gene signatures were constructed and evaluated for enriched functional terms. K-
means clustering was performed on the p-values associated with each term (Figure 3). 
Significantly enriched terms support previous findings in the literature: allergic diseases 
were enriched for “cell-cell adherens junction” (p-value=8.93×10−03), and 
hyperproliferative/neoplastic diseases were enriched for “keratinocyte and epithelial cell 
development” (p-value=2.47×10−09) (Cai et al., 2012; O’Regan et al., 2008). Wound, 
malignant, and infectious groups share overlapping enriched GO terms, associated with 
response to wounding.
Functional analysis of PM signatures shows enrichment for genes and pathways 
corresponding to single diseases
In order to assess the relevance of individual disease PM signatures, additional pathway 
analysis was performed on the 250 probe sets with the highest PM values for each disease. 
DAVID and Ingenuity Pathways functional analyses of individual disease signatures often 
showed a correspondence to the disease of origin (Tables S7, S8). For example, Ingenuity 
analysis of the melanoma PM signature revealed an enrichment of “biologic functions” 
relevant to melanocyte development and disorders (“differentiation of melanocytes,” p-
value=4.4×10−09), as well as a significant enrichment of the “Melanocyte Development and 
Pigmentation Signaling canonical pathway” (p-value=9.2×10−05) (Figure 4C). We 
developed a web-based visualization tool (http://pathways-pellegrini.mcdb.ucla.edu/
goTeles/dot_plot.html) that plots the expression of a gene within our database; shown are 
two melanocyte development genes (Figure 4A,B).
Network analysis of the PM signatures was carried out using Ingenuity Pathways Analysis 
to visualize connected genes and pathways in each disease and further evaluate the 
functional significance of our signatures. Notably, a psoriasis network showed connections 
between TCN1, OASL, and SPRR3 (Figure S6). This network appears to provide a cellular 
nexus connecting key pathogenesis elements, including differentiation-associated pathways, 
IFN-directed responses, and infiltrating inflammatory cells such as neutrophils. 
Furthermore, cell-type specific deconvolution of the psoriasis PM signature demonstrated 
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expression patterns consistent with the presence of neutrophils (Figure S7) (Fujimoto et al., 
1997; Suárez-Fariñas et al., 2012; Suárez-Fariñas et al., 2011; Swindell et al., 2013; Yao et 
al., 2008).
Type I vs. Type II interferon gene programs have a negative inverse correlation across a 
spectrum of skin diseases
Type I and Type II interferons (IFN) have opposing immunoregulatory roles in human 
disease, and previous work has shown different diseases or subtypes of disease to exhibit a 
range of IFN responses. Recent work in leprosy has demonstrated a distinct pattern of Th1 
versus Th2 cytokines, which we have used as a model for interrogating our skin disease 
database in order to identify similar patterns across a range of conditions (Teles et al., 2013; 
Wong et al., 2012; Yamamura et al., 1991). IFN–γ (Type II IFN) is involved in macrophage 
activation to fight bacterial infection, and is opposed by IFN–α/β (Type I IFN), which 
combats viral infection. Because IFNs are weakly detected on microarrays, we used Type I 
and Type II-specific induced transcriptional profiles of human peripheral blood 
mononuclear cells to infer the expression of IFN signatures (Teles et al., 2013; Waddell et 
al., 2010).
Integration of the IFN gene expression profiles with our data set containing 16 different skin 
conditions demonstrated a significant, inverse correlation between IFN–β and IFN–γ 
regulated genes across all skin diseases studied (r=−0.66, p-value=0.006), underscoring the 
opposing roles of IFN–β and IFN–γ in skin disease (Figure 5). The Stevens Johnson 
syndrome samples, which were obtained from blister fluid rather than full thickness 
biopsies, had the most extreme IFN–β IFN–γ profiles. Nevertheless, even if these samples 
were omitted, the anti-correlation between IFN–β vs. IFN–γ profiles was still significant (r=
−0.53, p-value=0.04).
Discussion
Insights into disease pathogenesis obtained by comparison of gene expression profiles are 
often limited because these comparisons are performed between either two different diseases 
or one disease versus healthy controls, and therefore cannot identify distinct and common 
mechanisms of pathogenesis. Here, we performed a cross-disease analysis of molecular 
profiles from multiple skin diseases. Using fRMA, it was possible to assemble a database of 
gene expression profiles from 311 samples spanning 16 conditions and visualize disease 
relationships on a hierarchical clustering tree. Remarkably we found that samples of a 
particular disease that were taken from different batches colocalized to the same branch. 
This was particularly striking in the case of normal skin, where five batches of samples 
taken from healthy control subjects not only clustered on the same branch, but were 
arranged with little differentiation by batch.
Our approach demonstrates that a multi-disease classifier can be built from disparate public 
data sources comprising over a dozen different conditions in a single tissue. We built this 
classifier from disease specific gene signatures, and found that it was accurate and robust to 
batch effect. The potential utility of molecular classification over the classic clinical criteria 
was demonstrated by the correct classification of an ambiguous case of psoriasis. A multi-
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disease classifier using epithelial cells from patients with psoriasis, atopic dermatitis, 
allergic contact dermatitis, and irritant contact dermatitis was previously constructed, 
although this was limited to diseases which had epidermal involvement (Kamsteeg et al., 
2010). Our work expands this principle to a wide range of both inflammatory and neoplastic 
diseases, and demonstrates the potential value of this approach in comparing diverse 
conditions. This approach can be expanded to include a more diverse spectrum of diseases, 
as more data is publicly available, allowing for the comparative study of diseases for which 
skin biopsy specimens may not be widely available.
We also analyzed this data by three supervised approaches: analysis of cell-type signatures, 
Gene Ontology pathways enrichment, and interferon response signatures. Together, these 
bioinformatic analyses provided insight into the distinct and related pathogenesis of the 
diseases. For example, hierarchical clustering of gene expression profiles revealed that 
leprosy and chancroid were located on the same branch which we termed “infectious” based 
upon their known etiologies. In the deconvolution analysis of cell type signatures, both 
diseases were characterized by the enrichment of similar lymphoid (CD3+, CD4+, CD8+, 
regulatory T cells, B cells) and myeloid (monocytes, macrophages, dendritic cells, 
neutrophils) expression profiles. Furthermore, Gene Ontology enrichment analysis identified 
the terms “lysosome”, “T cell differentiation” and “leukocyte adhesion”. Additionally, we 
found an anti-correlation of Type I and Type II IFN responses across a wide range of skin 
diseases of different etiologies, consistent with our previous studies using leprosy as a model 
(Teles et al., 2013). An earlier multi-disease comparison found that the magnitude of an IFN 
gene signature distinguished different inflammatory skin diseases, but could not distinguish 
between the Type I vs. Type II IFN patterns (Wong et al., 2012).
The present findings provide a rationale for further investigations to determine how these 
different IFN programs contribute to the pathogenesis of these diseases and identify 
treatment targets. The spectrum of IFN–β vs. IFN–γ gene program expression in the skin 
diseases studied here is consistent with current practices in treatment of skin disease. 
Typically, Type I IFN exhibits anti-proliferative effects, and is used to treat neoplasms, such 
as melanoma and BCC, which have a negative Type I IFN score. It should be noted that 
IFN–γ has been used to treat acute atopic dermatitis, even though chronic atopic dermatitis 
lesions, as studied here, express IFN–γ consistent with our findings (Alazemi and Campos, 
2006; Grassegger and Höpfl, 2004; Grewe et al., 1994; Grewe et al., 1995; Hamid et al., 
1994). Anti-IFN–γ has also been shown in preliminary studies to have a positive effect on 
Th1-mediated autoimmune skin diseases, including psoriasis, which we found had a high 
Type II IFN score (Skurkovich and Skurkovich, 2006).
High throughput analysis of gene expression profiles are a step towards the development of 
tools for personalized medicine. These studies have led to the discovery of individual genes 
and pathways that underlie disease pathology, which can be leveraged as biomarkers to 
diagnose and predict the course of disease, as well as identify targets for therapeutic 
intervention. For example, human leukocyte antigen (HLA) allele type has been linked to 
adverse responses to commonly used drugs such as the antiretroviral abacavir and the 
antiepileptic carbamazepine (Illing et al., 2013). Subsequent diagnostic tests would be based 
on such individual genes or sets of genes, making them more economical for clinical use. 
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The integrative molecular classification and functional analysis of multiple skin conditions 
reported here demonstrates the value of such a comparison to gain insight into the 
pathogenesis of human disease.
Materials and Methods
Microarray acquisition, processing, and clustering
Data was obtained from the NCBI Gene Expression Omnibus (GEO) as described in 
supplemental methods and Table S1 (http://www.ncbi.nlm.nih.gov/geo/) (Edgar et al., 
2002). Additional validation samples were obtained with written informed consent from de-
identified biopsy specimens as described in the supplement and Table S5. Data was 
normalized using the Frozen Robust Multiarray Average method and filtered by mean 
intensity of at least 15 in any disease. Unsupervised hierarchical clustering was used to 
group the normalized, filtered expression profiles using Pearson correlation.
Proportional median
Probe sets were ranked using the Proportional Median (PM), which we define as the median 
intensity of a probe set within one disease divided by the median intensity of the same probe 
set across all samples. For each disease, probe sets were ranked in descending order by PM.
Random forest classifier
A random forest classifier was built using the Matlab TreeBagger class (see supplemental 
methods for full description). The classifier feature space was reduced by selecting the 25 
probe sets with the highest PM values across the training set for each disease. Classifier 
validation was performed in three ways: three-fold cross validation, two-fold cross 
validation with separation by experimental batch where applicable, and external validation 
using independent samples.
Pathway analysis
The 250 probe sets with the highest PM value for each disease were selected for pathway 
analysis using Ingenuity Pathways Analysis (http://www.ingenuity.com) and DAVID 
Functional Annotation Analysis (http://david.abcc.ncifcrf.gov/), using the top 250 probe sets 
by PM from each disease signature (Huang et al., 2009a, b; www.ingenuity.com).
Cell-type specific signature enrichment
Cell-type specific expression profiles for 24 cell types were calculated as previously 
described and is described in more detail in the supplemental methods (Swindell et al., 
2013).
Group signatures
PM values were calculated for five disease group signatures, based on hierarchical 
clustering, and Gene Ontology enrichment was performed for each group (see supplement 
for details).
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IFN profile integration
IFN–β and IFN–γ specific scores were calculated by adapting a previously described method 
(see supplement for details) (Teles et al., 2013).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Unsupervised hierarchical clustering tree of 311 skin samples
Normalized, filtered gene expression profiles were clustered using gene expression distance 
(Pearson correlation) and displayed in a tree. Each terminal leaf in the tree represents a 
biopsy sample and is colored according to disease, with colored bars to the right 
representing the majority disease diagnosis. Samples that clustered apart from other samples 
of the same diagnosis can be seen a leaf that differs in color from its neighbors. Numbers 
following disease name labels denote batches of the same disease, and lists of numbers 
following a disease name denote multiple batches clustering to the same tree branch with 
little or no differentiation by batch. Brackets to the far right delineate biological groups of 
neighboring diseases.
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Figure 2. Cell-type specific signature enrichment
For each of 24 cell-type specific signatures, log fold changes were calculated using average 
gene expression for each condition. Each fold change represents the enrichment for a 
particular cell-type in that condition relative to the other 15 conditions. Enrichment profiles 
for each condition were clustered using Euclidean distance and displayed in a heatmap, 
where rows correspond to conditions and columns correspond to cell types. Black triangles 
denote FDR < 0.05 and directionality of fold change.
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Figure 3. Functional annotation and k-means clustering of group signatures
PM signatures for each biological group from unsupervised hierarchical clustering (Figure 
1) were calculated and annotated with enriched Gene Ontology (GO) terms. Corresponding 
false discovery rates (FDR) for each GO term were clustered using k-means clustering (k=8) 
and visualized in a heatmap, where rows correspond to GO terms and columns correspond to 
disease groups. Each gray bar represents the log10 FDR for a particular GO term in a 
particular disease group. Colored bars to the right demarcate clusters of GO terms, and a 
summary of terms and p-values are provided for each cluster.
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Figure 4. Visualization of melanoma proportional median (PM) signature
A,B. Visualization of normalized intensities for representative probe sets of MITF and TYR, 
two genes in the melanocyte development pathway. Each black circle represents an intensity 
value on a microarray for the specific probe set indicated. Red lines show median intensity 
values for each disease. Disease abbreviations are as follows: lepromatous leprosy (LLP), 
tuberculoid leprosy (TLP), reversal reaction leprosy (RR), erythema nodosum leprosum 
(ENL), chancroid (CH), mycosis fungoides (MF), sarcoid (SAR), Stevens Johnson 
Syndrome (SJS), psoriasis (PS), allergic contact dermatitis (ACD), irritant contact dermatitis 
(ICD), atopic dermatitis (ATD), burn (BU), acute wound (WA), post-operative wound 
(WPO), melanoma (MEL), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), 
normal skin (NS). C. Visualization of melanocyte development pathway in Ingenuity 
Pathways Analysis. The 250 probe sets with highest PM for melanoma were annotated for 
enriched functional pathways using Ingenuity Pathways Analaysis and one representative 
pathway is shown. Red genes indicate presence in a 250 probe set PM melanoma signature, 
with darker coloring denoting higher PM values. The melanocyte pathway was significantly 
enriched in the top 250 probe sets for melanoma (p-value=9.19×10−05).
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Figure 5. Type I and II interferon program cross-regulation
IFN–β and IFN–γ scores were calculated by ranking genes specifically regulated by IFN-β 
or IFN-γ relative to total gene expression and centering relative to the mean rank of each 
gene across all conditions. Individual up-or-down-regulated scores for each type of IFN 
were obtained by summing centered ranks, and an overall IFN score was obtained by 
subtracting the up-regulated sum of ranks by the down-regulated sum of ranks. Intuitively, 
high scores for each type of IFN represent high expression of IFN-stimulated genes, low 
expression of IFN-repressed genes, or both, such that placement on each axis shows the 
magnitude of expression of IFN–β or IFN–γ gene programs. The plot shows a significant 
negative inverse correlation (r=−0.66, p-value=0.006). Removing the outlier Stevens 
Johnson syndrome, the correlation remains significant (r=−0.53, p-value=0.04).
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Table 1
Two-fold cross validation, with separation by batch where applicable.
Condition Sensitivity Specificity Precision F1
Leprosy* 0.86 1.00 0.97 0.91
Psoriasis* 0.96 0.97 0.94 0.95
Chancroid 1.00 1.00 1.00 1.00
Allergic contact dermatitis 0.78 1.00 1.00 0.88
Irritant contact dermatitis 1.00 1.00 1.00 1.00
Atopic dermatitis* 0.95 0.99 0.88 0.91
Burn 1.00 1.00 1.00 1.00
Acute wound 0.83 1.00 1.00 0.91
Post-operative wound 1.00 1.00 1.00 1.00
Mycosis fungoides 1.00 1.00 1.00 1.00
BCC 0.87 1.00 0.93 0.90
Melanoma 0.86 0.98 0.67 0.75
SCC 0.60 1.00 0.86 0.71
Sarcoidosis 1.00 1.00 1.00 1.00
Stevens Johnson syndrome 0.80 1.00 1.00 0.89
Normal skin* 0.96 0.98 0.84 0.90
*
Denotes diseases separated by batch
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